Appendix 4E & Annual Report
Released
Released
Announcement PDF
Appendix 4E
Preliminary final report
1.
Details of reporting period
Name of entity
ABN
Reporting Year
Previous Corresponding Year
2.
Race Oncology Limited
61 149 318 749
Year ended 30 June 2024
Year ended 30 June 2023
Results for announcement to the market
832,577
12 months
ended 30
June 2023
$
591,839
Loss from ordinary activities after tax
attributable to members
(13,819,336)
Net loss for the year attributable to
members
Key information
12 months ended
30 June 2024
$
Revenues from ordinary activities
Net tangible asset per share
3.
Increase/
(decrease)
%
41%
Amount
change
$
240,738
(9,923,425)
(39%)
(3,895,911)
(13,819,336)
(9,923,425)
(39%)
(3,895,911)
0.091
0.137
Statement of profit or loss and other comprehensive income
Refer to attached financial statements.
4.
Statement of financial position
Refer to attached financial statements.
5.
Statement of cash flows
Refer to attached financial statements.
6.
Statement of changes in equity
Refer to attached financial statements.
7.
Dividends/Distributions
No dividends declared in current or prior year.
8.
Details of dividend reinvestment plans
N/A
9.
Details of entities over which control has been gained or lost during the year
N/A
10. Details of associate and joint venture entities
N/A
11. Any other significant information needed by an investor to make an informed assessment of the
Company’s financial performance and financial position
Refer to attached financial statements.
12. Foreign entities
On 6 October 2017, the Company incorporated a subsidiary in Belgium, Race Oncology, Company
Number 0682664917. There were no significant financial transactions through the subsidiary for the
year ended 30 June 2024.
13. Commentary on results for period and explanatory information
Race Oncology Limited incurred a net loss from operations for the financial year ended 30 June 2024
of $13,819,336 (2023: $9,923,425 loss). The net cash outflow from operating activities for the financial
year was $9,545,579 (2023: $10,651,551). At 30 June 2024, the Group had a cash balance of
$17,188,827 (2023: $21,520,368) and net assets of $18,312,148 (2023: $25,486,141).
14. Audit
This report is based on accounts which have been audited and the audit report is included in the
attached consolidated financial statements.
__________________________
Mary Harney - Chair
Authorised for release by the Board
27 August 2024
ASX: RAC
Annual Report 2024
At the heart of cancer care
Corporate
Directory
Directors
Ms Mary Harney Non-Executive Chair
Dr Peter Smith Executive Director
Mr Phillip Lynch Non-Executive Director
Company Secretary
Peter Webse
Registered office
Level 36, Gateway, 1 Macquarie Place
Sydney NSW 2000
Ph: +61 2 8051 3043
Website: www.raceoncology.com
Auditor
Hall Chadwick WA
283 Rokeby Road
Subiaco WA 6008
Securities Exchange Listing
Race Oncology Limited’s shares are listed on the
Australian Securities Exchange (ASX Code – RAC)
Share Registry
Automic Group
Level 5, 126 Phillip Street
Sydney NSW 2000
Ph: 1300 288 664
Race Oncology Limited
ACN 149 318 749
Contents
Chair Letter
2
2024 Key Highlights
4
Directors’ Report
6
Auditor’s Independence Declaration
20
Consolidated Statement of Profit or Loss
and Other Comprehensive Income
21
Consolidated Statement of Financial Position
22
Consolidated Statement of Changes in Equity
23
Consolidated Statement of Cash Flows
24
Notes to the Financial Statements
25
Directors’ Declaration
50
Independent Auditor’s Report
51
ASX Additional Information
56
Annual Report 2024
1
Chair
Letter
Dear fellow shareholders,
It is my privilege to welcome
you to Race Oncology’s
2024 Annual Report.
The past year saw us make robust progress on our
objective of taking the new bisantrene formulation,
RC220 into humans for the first time. Focus on this
target resulted in a series of milestone achievements,
which we touch on below and expand upon later in
this report:
We made significant progress in advancing RC220
bisantrene for use in human clinical trials. This saw
us complete manufacturing, undertake required
toxicology and safety pharmacology studies, and also
complete the selection and appointment process for
our Contract Research Organisation (CRO), culminating
in the appointment of George Clinical International.
Each of these activities is complex, time-consuming
and significant in its own right;
The release of a robust set of preclinical results showed
evidence of the anticancer and cardioprotective
activity of bisantrene both on its own and in a number
of different combinations with existing, marketed
therapies;
The confirmation of various designations from the
US Food and Drug Administration (FDA) for RC220
bisantrene, including Orphan Drug Designation and
Rare Paediatric Disease Designation – each of these
has the potential to confer meaningful regulatory
and commercial benefits during development and
at the point of approval. The latter also carries with
it the potential for Race Oncology (Race) to receive
a Priority Review Voucher (PRV) depending on the
likely continuation of that scheme;
2
Race Oncology Limited
Strengthened Scientific and Clinical Advisory Boards
as we welcomed internationally renowned clinicians
and scientists to join Race as consultants, including
Associate Professor Erin Howden of the Baker Heart and
Diabetes Institute (Melbourne, Australia), who joined
our Scientific Advisory Board, whose work in VO2Peak
is important to our focus in cardio-oncology. We also
established relationships with some of the key scientists
and clinicians who were involved in bisantrene’s initial
development, which has helped us further understand
the drug and its provenance. One such example is
distinguished oncologist Professor Daniel Von Hoff,
who has recently joined our Clinical Advisory Board.
Reflecting on a period of significant clinical progress
and key strategic milestones for Race, I’m encouraged
that our commitment to advancing cardioprotective
anticancer therapies has produced promising results,
supported by strong preclinical data and regulatory
acknowledgment.
Promising preclinical results
While RC220 bisantrene is being prepared for clinical
studies, a series of impressive preclinical results
reinforced that we have a unique drug asset in
bisantrene, owing to its anticancer and cardioprotective
properties.
Preclinical work performed at Oncolines BV yielded
results that showed bisantrene’s potent cancerkilling activity in 113/143 human cancer cell lines that
represented a broad cross-section of the most common
haematological (blood/liquid) and solid organ cancers
– an impressive outcome. When used in combination,
bisantrene improved the cancer-killing activities of
doxorubicin, an anthracycline chemotherapeutic and
one of the most widely used anticancer drugs, with
more than 20 million doses provided to patients around
the world each year.
Further preclinical work with Oncolines B.V.
(Netherlands) showed that bisantrene, in combination
with decitabine displayed enhanced cancer-killing
activity across a broad panel of 143 cancer cell lines,
representative of solid and blood cancers originating
from more than 20 different human tissues. Again, an
impressive result.
Preclinical work performed by Labcorp showed that
bisantrene, as a single agent treatment, was found to be
effective against human multiple myeloma in a mouse
model. More importantly, this preclinical result supports
further evaluation of bisantrene and carfilzomib
combination as a potentially more effective treatment
for multiple myeloma.
Readiness for human clinical studies
A considerable amount of effort was invested
throughout the year in preparing RC220 bisantrene for
its first human clinical trial. The planned Phase 1a/1b
trial of RC220 is an ‘all comers’ Bayesian dose escalation
study in solid tumour patients where doxorubicin use
is indicated.
With the support of our manufacturing partner Ardena
Holding NV, a leading contract development and
manufacturing organisation (CDMO), we completed
the first current Good Manufacturing Practice (cGMP)
batch of RC220 bisantrene, confirming that it meets
the quality specifications required for intravenous drug
product use in humans.
In addition, working alongside our partners Attentive
Science and Agilex Biolabs, we completed Good
Laboratory Practice (GLP) toxicology and safety
pharmacology studies on time and on budget. This
program included valuable dose-finding data that will
be used to support regulatory and ethics submissions
for the evaluation of RC220 bisantrene in human
clinical trials.
We welcomed the appointment of George Clinical
as CRO to support the pending Phase 1a/1b trial of
RC220 bisantrene, bringing access to a supplementary
network of key opinion leaders in clinical oncology.
Acute myeloid leukaemia in the spotlight
Post the reporting period, we were pleased to announce
that the RC110 bisantrene Phase 1b/2, the investigatorsponsored trial led by Professor Arnon Nagler at the
Chaim Sheba Medical Centre in Israel, had concluded
having met its endpoints.
Results showed that six of the 15 evaluable patients
(40%) with relapsed or refractory acute myeloid
leukaemia (AML) in the Phase 2 efficacy stage
responded to RC110 bisantrene in combination with
clofarabine and fludarabine (five complete responses,
one partial response).
Bringing bisantrene back to global
attention – supported by our team
and investors
I am tremendously proud of the work the Race team has
accomplished through the past year. It has reinforced
that we have a unique lead asset at hand in bisantrene,
and that our team is more than capable of taking it to
the next stage.
We have assembled a highly skilled and knowledgeable
team that brings a diverse range of expertise to the
company. I am delighted to see that Race continues to
attract leading professionals in our field to join us on
this journey.
I want to extend my deepest gratitude to both our
board Mr Phillip Lynch as Non-Executive Director, and
Dr Pete Smith as Executive Director and our team for
their unwavering dedication and exceptional efforts.
Led by Dr Daniel Tillett as Chief Executive Officer
(CEO), the team’s collective hard work and commitment
to excellence have been instrumental in driving our
success and advancing our mission.
We also extend our thanks to our investors for their
steadfast support and confidence in our vision over
the past year. We were once again supported by
shareholders through our Bonus Options offer, which
raised around 84% of its possible target. This was an
excellent result and one which gave us the confidence
to confirm we will proceed with the next investigatorsponsored trial in AML. We were enormously grateful to
have your support in a time that was otherwise difficult
in global capital markets.
At the end of FY2024, Race held $17.19 million in cash
and cash equivalents, compared to $21.52 million at
the end of FY2023. This change in balance resulted
from the funding of Race’s research and development
program, a significant manufacturing campaign and
ongoing operations. We were pleased to receive a
$4 million Research & Development (R&D) Tax Incentive
Refund from the Australian Taxation Office (ATO) in
February 2024.
As we move into FY2025, we are well capitalised to
complete our planned studies, and have an exciting
program ahead of us.
I wish to sincerely thank you for your ongoing support
of Race Oncology.
Although the study focused on the original RC110
formulation, the results have stimulated further clinician
interest in taking the drug forward in new AML trials.
We are in the process of discussing plans in this regard
with an Australian investigator in the AML field and will
announce them in due course.
Mary Harney
Chair
Race Oncology
Annual Report 2024
3
2024 Key
Highlights
July 2023
July 2023
August 2023
September 2023
September 2023
Race executes an
exclusive licence
agreement with
City of Hope to
access intellectual
property (IP)
covering bisantrene
as a potent inhibitor
of the human fat
mass and obesityassociated protein
(FTO).
Race enters into
an agreement with
Ardena Holding
NV, to provide
current cGMP
manufacturing
capability for RC220
bisantrene.
Changes announced
to the team, with
Mr Damian ClarkeBruce resigning
as CEO/Managing
Director (MD),
Dr Pete Smith
appointed Executive
Director, Dr Daniel
Tillett engaged as a
consultant, and Dr
John Cullity retiring
from the Board.
Race team revisits
strategic updates.
Race announced
preclinical results,
which showed
bisantrene’s
potent cancerkilling activity as
a single agent and
in combination
with doxorubicin,
bisantrene
was found to
significantly
enhance cell killing
in 85% of cancer
cell lines.
Race completes
manufacturing of
bisantrene active
pharmaceutical
ingredient (API)
at Laurus Labs,
certified as meeting
cGMP quality.
October 2023
October 2023
November 2023
November 2023
November 2023
Race contracts
Attentive Science
and Agilex Biolabs
to complete the
GLP toxicology
and safety
pharmacology
studies required
to support human
clinical trials using
RC220 bisantrene.
Race completes a
series of preclinical
animal and
laboratory studies
showing that RC220
bisantrene prevents
drug precipitation
(crystallisation)
and phlebitis (vein
inflammation
or damage)
when infused via
peripheral veins.
Race’s collaborators
present interim
clinical results
from an ongoing
InvestigatorSponsored Phase 2
AML Trial of RC110
bisantrene at the
American Society
of Hematology
(ASH) 65th Annual
Conference.
Race receives
Certificate of
Testing (CoT)
issued by Societal
CDMO for the
first engineering
batch of RC220
bisantrene,
confirming the drug
product meets
manufacturing
quality
specifications.
Race provides an
updated strategic
plan designed to
move its lead asset
RC220 bisantrene
through clinical
studies with the aim
to build significant
shareholder
value within the
constraints of
current capital
market conditions.
4
Race Oncology Limited
FY24 saw the preclinical progression of a new formulation
of bisantrene, RC220.
November 2023
February 2024
March 2024
March 2024
June 2024
Race appoints
Dr Daniel Tillett
as full-time CEO.
Race receives $4.0
million via the R&D
Tax Incentive from
the ATO for FY2023.
Race appoints
Associate Professor
Erin Howden to
Race’s Scientific
Advisory Board. Mr
Brendan Brown is
appointed as Chief
Financial Officer
(CFO).
Race receives
Certificate of
Analysis (CoA) for
the first current
cGMP batch of
2600 vials of
RC220 bisantrene,
confirming the
drug product
meets the quality
specifications
required for
human use.
Race receives
Orphan Drug
Designation (ODD)
from the FDA for
RC220 bisantrene.
June 2024
June 2024
June 2024
June 2024
Race shares results
of preclinical
work identifying
bisantrene as
a single-agent
treatment, to be
effective against
human multiple
myeloma in a
mouse model, and
more effective in
combination with
carfilzomib.
Race receives Rare
Paediatric Disease
Designation (RPDD)
from the FDA for
RC220 bisantrene
for the treatment of
paediatric AML.
Race appoints
George Clinical as
CRO to support
the clinical
development of
RC220 bisantrene.
Race completes
the GLP toxicology
and safety
pharmacology
studies for RC220
bisantrene.
Post reporting period
– July 2024
July 2024, Race appoints
distinguished oncologist
Professor Daniel Von
Hoff to the Race Clinical
Advisory Board. In
the same month, the
Phase 1b/2 AML trial
successfully concluded
at the Chaim Sheba
Medical Centre.
Annual Report 2024
5
Directors’ Report
Directors’ Report 30 June 2024
Your directors present their report, together with the financial statements of Race Oncology Limited (the Company, Race or
RAC), for the financial year ended 30 June 2024.
Information on directors
Directors have been in office since the start of the financial year to the date of this report unless otherwise stated.
Mary Harney
Qualifications
Experience
Interest in shares and options
Directorships held in listed entities
Peter Smith
Non-Executive Chair (appointed as Non-Executive Director 8 February 2021, appointed
as Chair 20 April 2023)
IDP-C INSEAD, BSc, BA (Fine Arts), MAICD FIML
Ms Harney is the Director of specialist consulting firm Mary Harney Advisory providing
leadership, governance and strategic advice across innovation industries such as
health, biotech and agriculture. She currently also serves as Chair of private Australian
biotech Oncology One Pty Ltd, a cancer drug discovery company, and Microbio Limited,
a diagnostic development company. Ms Harney was formerly the interim CEO of the
$2bn Breakthrough Victoria Fund, CEO of Royal Australasian College of Surgeons,
CEO of Gardiner Research Foundation, Chief Operating Officer (COO) and Director of
Office of Cancer Research for Peter MacCallum Hospital, and COO of Cerylid
Biosciences. Other former roles were with CSL, AMRAD, BIOPROPERTIES and Royal
Melbourne Hospital.
Personal & related party relevant interests:
•
Mary Celicia Harney <MMA Super Fund A/C> - 24,570 Fully Paid Ordinary Shares,
5,501 Piggyback options exercisable at $1.25, expiring 29/05/2026.
•
Mary Celicia Harney – 110,392 Options exercisable at $3.32, expiring 3/02/2028,
139,516 options exercisable at $1.39, expiring 1/12/2028.
None
Interest in shares and options
Executive Director (appointed as Non-Executive Director 28 June 2023, appointed as
Executive Director 24 August 2023)
BA, MSc (Natural Sciences), PhD (Cell Signalling)
Dr Smith has over 35 years of experience in the pharmaceutical and biotech industry,
with a strong focus on therapeutics, especially oncology. He has been involved in
projects at all stages from concept to phase III clinical studies.
He was previously the CEO of private biotechnology company Myrio Therapeutics, and
publicly listed Australian companies Alchemia and AMRAD.
Prior to moving to Australia, Dr Smith co-founded and was CFO of Onyvax Ltd, a cancer
immunotherapy company based in London. At the start of his career, he was a top-rated
Pharmaceuticals Analyst with UBS and HSBC, being involved in numerous transactions
including LSE/NASDAQ initial public offerings, fundraisings, and mergers & acquisitions
(M&A).
His undergraduate degree, master’s and doctorate are from the University of
Cambridge. He is also currently a Director of MycRx Inc. and Amala Therapeutics.
Personal & related party relevant interests:
Directorships held in listed entities
•
440,019 Options exercisable at $1.39, expiring 1/12/2028.
None
Qualifications
Experience
Phillip Lynch
Qualifications
Experience
6
Race Oncology Limited
Non-Executive Director (appointed as Non-Executive Director 1 June 2020, appointed
as CEO & MD 2 September 2020, ceased to be CEO & MD 1 February 2023)
BBus (Mktg), GAICD
Mr Lynch has a career spanning more than 30 years in the Asia Pacific region with
Johnson & Johnson (J&J AP). He is an experienced executive and board director, with
a diverse background across corporate development, strategy, financial performance,
marketing and governance.
In his former role as Vice President of Commercial Growth and Innovation J&J AP,
2016 - 2019, Mr Lynch partnered with the M&A team to drive the integration and growth
of acquired businesses. He retired from J&J AP in 2019 following the >$2b acquisition
and integration of a significant Japanese business.
He is currently the Chair of Consumer Health Products Australia.
Directors’ Report 30 June 2024
Information on directors (cont’d)
Phillip Lynch (cont’d)
Interest in shares and options
Personal & related party relevant interests:
•
2,000,000 Options exercisable at $2.65 expiring 29/11/2025.
Lynch Eventide Holdings Pty Ltd <Lynch Family A/C> - 450,606 Fully Paid
Ordinary Shares, 64,371 Piggyback options exercisable at $1.25, expiring
29/05/2026.
None
•
Directorships held in listed entities
Damian Clarke-Bruce
Qualifications
Experience
Interest in shares and options
Directorships held in listed entities
John Cullity
Qualifications
Experience
Interest in shares and options
Directorships held in listed entities
MD and CEO (appointed 1 February 2023, resigned 21 August 2023)
BSpSc, MSc, PGd RC, PGd GenMg
Mr Clarke-Bruce is an experienced international healthcare executive, having worked
in the biopharmaceutical and healthcare industries for over 25 years.
Prior to joining Race, he served as the Global/US Executive Director of Marketing in
Rare Disease for Pharming NV, a Netherlands/US Biopharma Company. Mr ClarkeBruce’s career has also spanned multiple global pharmaceutical companies, including
Celgene, Novartis & Biogen.
Personal & related party relevant interests:
•
6,818 Fully Paid Ordinary Shares held at date of resignation 21 August 2023.
•
755,671 Options exercisable at $3.30 lapsed on date of resignation 21 August
2023.
None
Non-Executive Director (appointed as Non-Executive Director 6 April 2018, ceased to
be Chair 20 April 2023, and retired as Non-Executive Director 21 August 2023)
MBBS, MRCP, MSc (Econs), MBA
Dr Cullity is MD at BioSynergy Partners, a New York and Melbourne based advisory
recently spun out of Torreya. He additionally serves on the Boards of several life
sciences companies including Ceramedix (seeded by Torreya). At Torreya, he provided
strategic advisory on M&As, Partnering and Financing to life-science companies
worldwide. Prior to joining Torreya, he was a senior member of the Business
Development team at Sanofi Pharmaceuticals.
Personal & related party relevant interests:
•
Biosynergy Partners Pty Ltd – 6,102,194 Fully Paid Ordinary Shares held at date
of resignation 21 August 2023.
•
Craganorig Holdings, LLC – 2,000,000 Fully Paid Ordinary Shares held at date of
resignation 21 August 2023.
None
Annual Report 2024
7
Directors’ Report
Directors’ Report 30 June 2024
Information on officer holders and Key Management Personnel
Office Holders and Key Management Personnel (KMP) have been in their roles since the start of the financial year to the date
of this report unless otherwise stated.
Peter Webse
Company Secretary
Qualifications
BBus, FGIA, FCIS, FCPA.
Experience
Mr Webse has over 30 years' company secretarial experience and is the director of
Governance Corporate Pty Ltd, a company specialising in providing company
secretarial, corporate governance and corporate advisory services.
Daniel Tillett
CEO (appointed 22 November 2023)
Qualifications
BS (HonsI), PhD (Molecular Genetics & Biochemistry)
Experience
Dr Tillett is the CEO and founder of Nucleics Pty Ltd, a private Australian biotechnology
company producing and selling world-leading DNA sequencing software to the
genomics industry. Nucleics SAAS (software as a service) genomics tools are used in
more than 30 countries and at over 250 companies and research institutions. Dr Tillett
was previously an Executive Director and Chief Scientific Officer (CSO) at Race from
17 September 2019 and 1 October 2019, respectively and resigned from both roles on
21 March 2023. Dr Tillett was a Senior Lecturer within the School of Pharmacy at La
Trobe University where he taught and researched in the areas of pharmacy, phage
therapy, virology, microbiology, bioinformatics and cancer. Dr Tillett’s PhD on the
molecular genetics and biochemistry of microcystin toxin production was awarded by
the University of New South Wales in 2000. He has more than 40 scientific publications
and granted patents in molecular biology, virology, microbiology, genetics and
biochemistry.
Personal & related party relevant interests:
•
17,267,615 Fully Paid Ordinary Shares, 2,448,342 Piggyback options exercisable
at $1.25, expiring 29/05/2026.
Interest in shares and options
•
•
2,000,000 Options exercisable at $2.65, expiring 29/11/2025.
1,534,712 Options exercisable at $1.45, expiring 29/11/2028.
Directorships held in listed entities
•
3,061,101 Options exercisable at $4.25, expiring 29/11/2028.
Simble Solutions Limited (Non-Executive Director appointed 16 February 2022,
resigned 3 July 2023)
Michelle Rashford
Chief Medical Officer (CMO) (appointed 1 July 2023)
Qualifications
BMedSci, MBBS
Experience
Interest in shares and options
Dr Rashford is an internationally experienced biopharmaceutical executive and former
physician, with expertise in the successful development and commercialisation of
pharmaceuticals across oncology, virology, and immunology. Her 30 years of drug
development experience spans large pharmaceuticals to smaller biotech companies
and includes clinical development, medical and regulatory affairs, and drug
commercialisation. Prior to joining Race, Dr Rashford worked for Japanese
Pharmaceutical company Kyowa Kirin, where she was the Head of Global Clinical
Sciences. Prior to her role at Kyowa Kirin, Dr Rashford was the Senior Vice President
of Clinical Science at Adlai Nortye Biopharma, where she successfully grew the US
Clinical Development team and prepared for the company’s Phase III trial. She has also
held senior roles within global pharmaceutical companies, including five years at BristolMyers Squibb and close to 20 years at Roche in a variety of national and global clinical
development roles.
Personal & related party relevant interests:
Directorships held in listed entities
•
1,116,083 Options exercisable at $1.95, expiring 1/11/2028.
None
8
Race Oncology Limited
Directors’ Report 30 June 2024
Principal activities
Race Oncology (ASX: RAC) is an Australian Securities Exchange (ASX)-listed clinical stage biopharmaceutical company with
a dedicated mission to be at the heart of cancer care.
Race’s lead asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a rich and unique clinical history with
demonstrated therapeutic benefits in both adult and paediatric patients, a well-characterised safety profile, and compelling
preclinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin.
Race is advancing a reformulation of bisantrene (RC220) to address the high unmet needs of patients across multiple
oncology indications, with a clinical focus on anthracycline combinations, where we hope to deliver cardioprotection and
enhanced anti-cancer activity in solid tumours. Race is also exploring RC220 bisantrene as a low-intensity treatment for AML.
Race is investigating the effect of bisantrene on the m6A ribonucleic acid (RNA) pathway, following independent research
published by the City of Hope identifying bisantrene as a potent inhibitor of FTO. Dysregulation of the m6A RNA pathway has
been described in numerous peer reviewed studies as a driver of a diverse range of cancers.
Race Oncology has collaborated with Astex, City of Hope, MD Anderson, Sheba City of Health, UNC School of Medicine,
University of Wollongong and University of Newcastle, and is actively exploring partnerships, licence agreements or a
commercial merger and acquisition to accelerate access to bisantrene for patients with cancer across the world.
Outlook
At the time of writing, Race is advancing RC220 bisantrene into the clinic as an anticancer and cardioprotective agent in
combination with doxorubicin in solid tumour patients. Race is also in discussion to support an investigator sponsored trial of
RC220 bisantrene in AML patients in combination with decitabine.
After the successful raise of $5 million in June 2024, via a strongly supported bonus option issue, Race is well funded to
undertake both a company sponsored Phase 1a/b trial in solid tumours and an investigator sponsored Phase 1/2 trial in AML.
All preclinical and manufacturing activities required for the use of RC220 in these human clinical trials were completed in
FY2024. The company looks forward to updating our shareholders on the progress towards ethics and governance approval,
site initiation and the first patient on trial in the coming months.
Overview of company performance
The table below sets out information about Race's earnings and movements in shareholder wealth for the past five years up
to and including the current financial year.
2024
$
Net profit after tax (NPAT) ($'m)
Share price at year end ($)
Basic earnings per share (EPS) (cents)
Total dividends (cents per share)
(13.82)
1.82
(8.40)
-
2023
$
(9.92)
1.23
(6.17)
-
2022
$
2021
$
(11.20)
1.95
(7.28)
-
(6.34)
3.67
(4.84)
-
2020
$
(3.85)
0.70
(3.60)
-
Meetings of directors
During the financial year, 11 meetings of directors (including committees of directors) were held. Attendances by each director
during the year were as follows:
Directors' meetings
Number eligible to attend
Number attended
Mary Harney
11
11
Phillip Lynch
11
11
Peter Smith
11
11
Damian Clarke-Bruce
1
1
John Cullity
1
-
Annual Report 2024
9
Directors’ Report
Directors’ Report 30 June 2024
Operating results
The operating loss after providing for income tax amounted to $13,819,336 (2023: loss of $9,923,425); net cash used in
operating activities was $9,545,579 (2023: $10,651,551).
Dividends paid or recommended
No dividends were paid or are payable for the financial year (2023: Nil).
Review of operations
The following section summarises ASX updates from the 2024 financial year:
On 10 July 2023, Race executed an exclusive licence agreement with City of Hope to access IP identifying bisantrene as a
potent inhibitor of the human FTO. The Agreement ensures Race’s exclusive access to that IP.
On 12 July 2023, Race announced that it had entered into an agreement with a leading global CDMO, Ardena Holding NV, to
provide current cGMP manufacturing capability for Race’s proprietary intravenous formulation of bisantrene, RC220.
On 22 August 2023, Race announced management changes with Mr Damian Clarke-Bruce resigning as CEO & MD and Dr
John Cullity retiring from the Race Board. Dr Pete Smith was appointed an Executive Director, and former CSO Dr Daniel
Tillett was engaged as a consultant. The Race Board announced a strategic review to ensure the delivery of research and
clinical milestones within cu
Share your feedback
Discover